Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Expands Color-Shifting Labels Beyond Viagra To Celebrex, Lipitor

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer is expanding its use of color-shifting labels beyond Viagra to five other products as part of its anti-counterfeiting efforts.

You may also be interested in...



FDA Alerts U.S. Residents To British Recall Of Counterfeit Lipitor

U.S. residents may have received the counterfeit statin if they purchased drugs online, from storefront operations that supply unapproved drugs, or through state-run drug importation programs, FDA warns.

FDA Alerts U.S. Residents To British Recall Of Counterfeit Lipitor

U.S. residents may have received the counterfeit statin if they purchased drugs online, from storefront operations that supply unapproved drugs, or through state-run drug importation programs, FDA warns.

FDA To Examine Safety Impact Of Color In Drug Labeling, Packaging

A March 7 public hearing will help the agency determine the benefits and potential drawbacks to patient safety. FDA seeks input on whether there are specific classes of drugs where use of color has demonstrated value or posed a hindrance to public safety.

Related Content

Topics

UsernamePublicRestriction

Register

MT101489

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel